Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A.

Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24.

PMID:
14613032
2.

Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Ran S, Huang X, Downes A, Thorpe PE.

Neoplasia. 2003 Jul-Aug;5(4):297-307. doi: 10.1016/S1476-5586(03)80023-4.

3.

Synergy between vascular targeting agents and antibody-directed therapy.

Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RH.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1524-31.

PMID:
12459381
4.

Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.

Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A.

Hum Pathol. 2002 Sep;33(9):863-70.

PMID:
12378509
5.

Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.

McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ.

J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44.

PMID:
12213878
6.

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.

Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller-Tidow C, Serve H, Berdel WE, Mesters RM.

Leukemia. 2002 Jul;16(7):1302-10.

7.

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941.

8.

Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2002 Jun;8(6):1816-21.

9.

Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.

Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA.

J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166.

PMID:
11992800
10.
11.

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.

Siemann DW, Mercer E, Lepler S, Rojiani AM.

Int J Cancer. 2002 May 1;99(1):1-6.

12.

Receptor tyrosine kinase inhibitors.

Haluska P, Adjei AA.

Curr Opin Investig Drugs. 2001 Feb;2(2):280-6. Review.

PMID:
11816845
13.

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, Fidler IJ.

Cancer Biother Radiopharm. 2001 Oct;16(5):359-70.

PMID:
11776753
15.
17.

The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.

Clin Cancer Res. 2000 Dec;6(12):4848-58.

18.

The role of VEGF and thrombospondins in skin angiogenesis.

Detmar M.

J Dermatol Sci. 2000 Dec;24 Suppl 1:S78-84. Review.

PMID:
11137400
19.

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C, Marmé D.

Cancer Res. 2000 Sep 1;60(17):4819-24.

20.

Tumor angiogenesis, macrophages, and cytokines.

Bando H, Toi M.

Adv Exp Med Biol. 2000;476:267-84. Review. No abstract available.

PMID:
10949671

Supplemental Content

Support Center